Clinical trials: past, present and future
Treatment-resistant depression (TRD) is a significant challenge for patients and mental health professionals. It affects a considerable percentage of people with major depression who find no relief from conventional antidepressant therapies. In this context, scientific interest in the therapeutic potential of psychedelic substances is surging again, and Spain is no exception. Although cautiously and under strict controls, some Spanish public hospitals are beginning to explore these avenues through controlled clinical trials.
Esketamine: an established precedent in the national health system
The most established example within Spain’s National Health System (SNS) of innovative therapies for resistant depression is esketamine, the S(+) enantiomer of racemic ketamine. It is not a “derivative” in the strict sense but one of its two molecular forms, with different pharmacological properties and a higher affinity for the NMDA receptor, which translates into more potent effects at a lower dose.
Since the end of 2022, esketamine has been funded by Spanish public healthcare in its intranasal formulation — marketed as Spravato® — for the treatment of episodes of resistant depression in adults, in combination with an oral antidepressant. Its use is limited to strictly controlled hospital administration, with at least two hours of observation after each dose, because of its possible side effects (transient rise in blood pressure, mild dissociation, sedation).
Meanwhile, intravenous racemic ketamine, used off-label, has proliferated mainly in private clinics, where it is given in controlled settings but with non-uniform criteria and protocols. The inclusion of esketamine in the public pharmaceutical catalogue was a symbolic and therapeutic turning point: it was the first molecule with psychedelic action authorised and funded within the SNS for a serious psychiatric disorder, paving the way for future fast-acting therapies with unconventional mechanisms to be considered within the institutional sphere.
Psilocybin: the spearhead of public clinical research
Among the classic psychedelics, psilocybin — the main active alkaloid of mushrooms of the genus Psilocybe — is today the substance with the most advanced clinical research in relation to resistant depression. Its pharmacological profile, its intermediate duration and its history of use in scientific and ritual contexts make it an ideal candidate for study in controlled settings.
In Spain, several reference centres have started or are processing controlled clinical trials with psilocybin under the authorisation of the Spanish Agency of Medicines and Medical Devices (AEMPS) and with the approval of hospital ethics committees. The Hospital Sant Pau in Barcelona, known for its track record in precision psychiatry, is among the most advanced, and other centres in Madrid and other autonomous communities are expected to join in the short term.
These trials are characterised by a rigorous methodology, comparing psilocybin administration with placebo or active treatments in well-defined samples of patients with treatment-resistant depression (TRD). The protocol is not limited to drug administration: it includes prior psychotherapeutic preparation, support during the session (usually with two therapists) and integration processes afterwards that make it possible to turn the psychedelic experience into a lasting therapeutic resource.
Participant selection is also very strict: only people with a confirmed diagnosis of TRD after multiple treatment failures are admitted, and psychiatric, medical and social exclusion criteria are applied to maximise safety. All procedures take place in carefully designed clinical environments, which combine hospital infrastructure with elements of emotional containment and reduction of adverse stimuli.
This type of trial represents a historic first in the Spanish public health system. Never before had a classic psychedelic been given in a public hospital with therapeutic aims and a scientifically approved design. The success of this research could pave the way for future approvals and structured clinical protocols to treat cases of depression that have exhausted conventional routes.
What about 5-MeO-DMT?
Besides psilocybin, another psychedelic compound that has begun to attract scientific attention for treating mental disorders is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). This tryptamine — found in some traditional plants and in the venom of the toad Incilius alvarius — stands out for its very rapid, short-lived action, which makes it an interesting candidate for clinical studies in conditions such as resistant depression.
In Spain, formal clinical evidence with 5-MeO-DMT is still at an early stage, but there are already concrete moves confirming that interest is not confined to the experimental or anecdotal sphere. For example, the Hospital Sant Joan de Déu in Barcelona launched a recruitment drive for volunteers for studies with 5-MeO-DMT in people with resistant depression, with the aim of better understanding the substance’s therapeutic potential in the context of mental health.
In parallel, there are international clinical trials (phase I/II) assessing the safety, tolerability and effects on anxiety and depression of sublingual 5-MeO-DMT formulations in double-blind, placebo-controlled designs. These studies aim to generate solid data on the substance’s pharmacokinetics and effect profile, laying the groundwork for later research that could include national samples.
Although the scientific literature is still limited, preliminary evidence suggests that 5-MeO-DMT may show an acceptable short-term safety profile in controlled settings and potential benefits for symptoms of depression and anxiety. A recently published phase I trial documents the safety and pharmacokinetics of sublingual microdoses in adults with anxiety and depression, an important step before assessing broader clinical efficacy.
Beyond strictly clinical trials, there are also observational studies and surveys indicating self-reported improvements in depression, anxiety and wellbeing after 5-MeO-DMT experiences in structured settings. Although these data are no substitute for controlled trials, they provide hypotheses and directions for future research.
Overall, 5-MeO-DMT represents a promising experimental paradigm that is complementary to other psychedelics under research. Its short-acting profile and intense subjective impact lead many researchers to consider it potentially useful for hard-to-treat conditions such as treatment-resistant depression, although larger and more rigorous trials are still needed to confirm its safety, efficacy and clinical applicability.
LSD for depression?
LSD (lysergic acid diethylamide) has a long history in twentieth-century psychiatric research. In the current context, however, its clinical use is still limited by regulatory, media and duration factors — LSD sessions tend to be longer than psilocybin sessions, which means greater logistical and human-resource demands. Even so, trials in other European countries, such as Switzerland and Germany, have resumed research with LSD in therapeutic settings, which could open the door to future initiatives in Spain too if results are solid and reproducible.
In recent years, LSD has undergone a gradual scientific renaissance in psychiatric research, after decades of interruption due to regulatory restrictions. Recent studies have assessed the safety, tolerability and possible antidepressant effects of therapy assisted by controlled doses of LSD in patients with major depressive disorder, showing significant reductions in symptoms in phase II trials and supporting the need for larger, more rigorous trials to confirm its clinical efficacy and safety. These designs — comparing high doses with low doses or placebo in combination with psychotherapy — have documented improvements on depression scales that last for weeks and underline the renewed interest in this molecule as a therapeutic alternative, although its classification as a controlled substance and the need for highly supervised settings remain important regulatory barriers.
Challenges and the future
Institutional and scientific interest in psychedelic therapies in the public sphere is growing, but the transition from research to clinical implementation means overcoming numerous structural, logistical and cultural challenges.
One of the main challenges is training specialised staff. Psychedelic-assisted therapy requires not only general clinical knowledge but also specific skills in emotional support, working with non-ordinary states of consciousness and the ability to sustain complex integration processes. In this sense, creating accredited training pathways within the public health system will be key to responsible implementation.
In addition, current hospital settings are not always prepared to host this type of intervention. The need for quiet spaces, free of clinical noise, with adjustable lighting and enough privacy for patients to go through their experience with safety and emotional containment requires rethinking therapeutic architecture. It is not just a matter of authorising substances, but of designing suitable conditions for their use.
On top of all this comes the cultural and political factor. Resistance, stigma and fear persist among parts of the medical, political and media establishment, who associate these substances with counterculture or recreational use. Evidence-based public education, the push from professional associations and the visibility of rigorously documented clinical cases can help change this perception.
Finally, the design of scalable clinical protocols that properly integrate the psychotherapeutic and pharmacological parts will be crucial for these therapies to fit within the logic of the National Health System. Without replicable and sustainable models, even the most successful trials could remain experiments without continuity.
Conclusion
Spanish public healthcare has begun to explore the therapeutic potential of psychedelics cautiously but firmly in the treatment of resistant depression. The case of esketamine, already approved and included in the SNS therapeutic arsenal, set a precedent that has allowed progress towards clinical trials with psilocybin in leading public hospitals. These studies, still under way, are an unprecedented opportunity to validate innovative treatments in populations that have not responded to conventional therapies.
However, moving from research to implementation will require political will, institutional investment and a gradual transformation of clinical culture. Training professionals, creating suitable therapeutic spaces and integrating the psychotherapeutic dimension as an inseparable part of the process are key to ensuring that access to these therapies, if approved, is not restricted to a private elite but is part of the right to comprehensive mental health care.
Spain, with its hospital network, its excellent research teams and growing social openness to emerging therapies, has the opportunity to position itself as a European reference in treating resistant depression with psychedelics. Time and clinical evidence will tell whether this window opens fully. In the meantime, research moves forward. And with it, the hope of those who have already tried too many dead ends.



